Efficacy of live attenuated vaccines after two doses of intravenous immunoglobulin for Kawasaki disease

作     者：Yoshihiko Morikawa Hiroshi Sakakibara Masaru Miura Yoshihiko Morikawa;Hiroshi Sakakibara;Masaru Miura

作者机构：Clinical Research Support CenterTokyo Metropolitan Children’s Medical Center2-8-29 MusashidaiFuchuTokyo183-8561Japan Department of General PediatricsTokyo Metropolitan Children’s Medical CenterTokyoJapan Department of CardiologyTokyo Metropolitan Children’s Medical CenterTokyoJapan 

出 版 物：《World Journal of Pediatrics》 (世界儿科杂志（英文版）)

年 卷 期：2022年第18卷第10期

页      面：706-709页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100202[医学-儿科学] 10[医学] 

基　　金：supported by a grant from the Tokyo Metropolitan Government and the Japan Kawasaki Disease Research Center 

主　　题：doses attenuated intravenous 

摘      要：Kawasaki disease(KD)is a vasculitis of unknown etiology occurring predominantly in children under five years old[1].Coronary artery aneurysm,its most serious complica-tion,occurs in about 25%of untreated patients[2].High-dose intravenous immunoglobulin(IVIG)2 g/kg is used to prevent coronary artery aneurysms[1,3,4],but about 20%of patients are nonresponsive and require a second dose for a total of 4 g/*** appropriate timing of live attenuated vaccine(LAV)administration in such cases is unclear.